AstraZeneca Capital Expenditures from 2010 to 2024

AZN Stock   10,468  100.00  0.95%   
AstraZeneca PLC's Capital Expenditures is increasing over the years with stable fluctuation. Capital Expenditures is expected to dwindle to about 1.9 B. During the period from 2010 to 2024 AstraZeneca PLC Capital Expenditures annual values regression line had geometric mean of  2,104,010,008 and mean square error of 1015325.1 T. View All Fundamentals
 
Capital Expenditures  
First Reported
1999-09-30
Previous Quarter
668 M
Current Value
1.4 B
Quarterly Volatility
534.3 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check AstraZeneca PLC financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AstraZeneca PLC's main balance sheet or income statement drivers, such as Depreciation And Amortization of 5.2 B, Interest Expense of 1.7 B or Total Revenue of 24.2 B, as well as many indicators such as . AstraZeneca financial statements analysis is a perfect complement when working with AstraZeneca PLC Valuation or Volatility modules.
  
This module can also supplement various AstraZeneca PLC Technical models . Check out the analysis of AstraZeneca PLC Correlation against competitors.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in AstraZeneca Stock

AstraZeneca PLC financial ratios help investors to determine whether AstraZeneca Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AstraZeneca with respect to the benefits of owning AstraZeneca PLC security.